Remimazolam vs Propofol as an Induction Agent for Morbid Obesity Patients

• Status: Recruiting
• Trial end date: 2023-09-12
• Target enrollment: 0
• Participant gender: All

Summary

It is known that morbidly obese patients are often accompanied by cardiovascular complications such as hypertension, cardiac hypertrophy, and diastolic dysfunction, and are known to increase the risk of hypotension during anesthesia induction. Remimazolam is widely used in Japan and the United States, and it was approved as a drug for general anesthesia and sedation in Korea in 2021. It was reported that remimazolam caused less hypotension after induction of anesthesia than propofol. However, there is no study on the use of remimazolam in patients undergoing bariatric surgery due to morbid obesity. Therefore, through this study, we plan to check whether remimazolam is safe and effective as an anesthetic-inducing agent for morbidly obese patients undergoing bariatric surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital

Criteria

Inclusion Criteria:

• =or > 20 years

• Admission for General anesthesia for sleeve gastrectomy

Exclusion Criteria:

• No severe adverse effect history or hypersensitivity of benzodiazepines or its additives

• Acute alcoholic intoxication state

• Coma or shock state due to other condition than heart problem.

• Acute narrow-angle glaucoma